Cargando…
Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
BACKGROUND: Hepatitis B infection is still the main cause of chronic liver disease in Iran, which is associated with significant economic and social costs. OBJECTIVES: This study aimed to estimate the financial burden caused by CHB infection and its complications in Iran. PATIENTS AND METHODS: Preva...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427913/ https://www.ncbi.nlm.nih.gov/pubmed/25977694 http://dx.doi.org/10.5812/hepatmon.15(4)2015.25854 |
_version_ | 1782370798732836864 |
---|---|
author | Keshavarz, Khosro Kebriaeezadeh, Abbas Alavian, Seyed Moayed Akbari Sari, Ali Abedin Dorkoosh, Farid Keshvari, Maryam Malekhosseini, Seyed Ali Nikeghbalian, Saman Nikfar, Shekoufeh |
author_facet | Keshavarz, Khosro Kebriaeezadeh, Abbas Alavian, Seyed Moayed Akbari Sari, Ali Abedin Dorkoosh, Farid Keshvari, Maryam Malekhosseini, Seyed Ali Nikeghbalian, Saman Nikfar, Shekoufeh |
author_sort | Keshavarz, Khosro |
collection | PubMed |
description | BACKGROUND: Hepatitis B infection is still the main cause of chronic liver disease in Iran, which is associated with significant economic and social costs. OBJECTIVES: This study aimed to estimate the financial burden caused by CHB infection and its complications in Iran. PATIENTS AND METHODS: Prevalence-based and bottom-up approaches were used to collect the data. Data on direct medical costs were extracted from outpatient medical records in a referral gastroenterology and hepatology research center, inpatient medical records in several major hospitals in Tehran and Shiraz in 2013, and the self-reports of specialists. Data on direct non-medical and indirect costs were collected based on the patients’ self-reports through face-to-face interviews performed in the mentioned centers. To calculate the indirect costs, friction cost approach was used. To calculate the total cost-of-illness in Iran, the total cost per patient at each stage of the disease was estimated and multiplied by the total number of patients. RESULTS: The total annual cost for the activate population of CHB patients and for those receiving treatment at various disease stages were respectively 450 million and 226 million dollars, with 64% and 70% of which allocated to direct costs respectively, and 36% and 30% to indirect costs respectively. The total direct costs alone for each group were respectively 1.17% and 0.6% of the total health expenditure. Furthermore, the cost spent on drugs encompasses the largest proportion of the direct medical cost for all stages of the disease. CONCLUSIONS: According to the perspectives of payers, patients, and community, CHB infection can be considered as one of the diseases with a substantial economic burden; the disease, specifically in extreme cases, can be too expensive and costly for patients. Therefore, patients should be protected against more severe stages of the disease through proper treatment and early diagnosis. |
format | Online Article Text |
id | pubmed-4427913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Kowsar |
record_format | MEDLINE/PubMed |
spelling | pubmed-44279132015-05-14 Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran Keshavarz, Khosro Kebriaeezadeh, Abbas Alavian, Seyed Moayed Akbari Sari, Ali Abedin Dorkoosh, Farid Keshvari, Maryam Malekhosseini, Seyed Ali Nikeghbalian, Saman Nikfar, Shekoufeh Hepat Mon Research Article BACKGROUND: Hepatitis B infection is still the main cause of chronic liver disease in Iran, which is associated with significant economic and social costs. OBJECTIVES: This study aimed to estimate the financial burden caused by CHB infection and its complications in Iran. PATIENTS AND METHODS: Prevalence-based and bottom-up approaches were used to collect the data. Data on direct medical costs were extracted from outpatient medical records in a referral gastroenterology and hepatology research center, inpatient medical records in several major hospitals in Tehran and Shiraz in 2013, and the self-reports of specialists. Data on direct non-medical and indirect costs were collected based on the patients’ self-reports through face-to-face interviews performed in the mentioned centers. To calculate the indirect costs, friction cost approach was used. To calculate the total cost-of-illness in Iran, the total cost per patient at each stage of the disease was estimated and multiplied by the total number of patients. RESULTS: The total annual cost for the activate population of CHB patients and for those receiving treatment at various disease stages were respectively 450 million and 226 million dollars, with 64% and 70% of which allocated to direct costs respectively, and 36% and 30% to indirect costs respectively. The total direct costs alone for each group were respectively 1.17% and 0.6% of the total health expenditure. Furthermore, the cost spent on drugs encompasses the largest proportion of the direct medical cost for all stages of the disease. CONCLUSIONS: According to the perspectives of payers, patients, and community, CHB infection can be considered as one of the diseases with a substantial economic burden; the disease, specifically in extreme cases, can be too expensive and costly for patients. Therefore, patients should be protected against more severe stages of the disease through proper treatment and early diagnosis. Kowsar 2015-04-25 /pmc/articles/PMC4427913/ /pubmed/25977694 http://dx.doi.org/10.5812/hepatmon.15(4)2015.25854 Text en Copyright © 2015, Kowsar Corp. http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited. |
spellingShingle | Research Article Keshavarz, Khosro Kebriaeezadeh, Abbas Alavian, Seyed Moayed Akbari Sari, Ali Abedin Dorkoosh, Farid Keshvari, Maryam Malekhosseini, Seyed Ali Nikeghbalian, Saman Nikfar, Shekoufeh Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran |
title | Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran |
title_full | Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran |
title_fullStr | Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran |
title_full_unstemmed | Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran |
title_short | Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran |
title_sort | economic burden of hepatitis b virus-related diseases: evidence from iran |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427913/ https://www.ncbi.nlm.nih.gov/pubmed/25977694 http://dx.doi.org/10.5812/hepatmon.15(4)2015.25854 |
work_keys_str_mv | AT keshavarzkhosro economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran AT kebriaeezadehabbas economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran AT alavianseyedmoayed economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran AT akbarisariali economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran AT abedindorkooshfarid economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran AT keshvarimaryam economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran AT malekhosseiniseyedali economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran AT nikeghbaliansaman economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran AT nikfarshekoufeh economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran |